Hypertension treatment in sub-Saharan Africa: a systematic review.

IF 0.7 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiovascular Journal of Africa Pub Date : 2023-11-23 Epub Date: 2023-05-25 DOI:10.5830/CVJA-2022-065
Pauline Cavagna, Céline Leplay, Roland N'Guetta, Kouadio Euloge Kramoh, Ibrahima Bara Diop, Dadhi M Balde, Jean Bruno Mipinda, Michel Azizi, Xavier Jouven, Marie Antignac
{"title":"Hypertension treatment in sub-Saharan Africa: a systematic review.","authors":"Pauline Cavagna, Céline Leplay, Roland N'Guetta, Kouadio Euloge Kramoh, Ibrahima Bara Diop, Dadhi M Balde, Jean Bruno Mipinda, Michel Azizi, Xavier Jouven, Marie Antignac","doi":"10.5830/CVJA-2022-065","DOIUrl":null,"url":null,"abstract":"<p><p>Sub-Saharan Africa (SSA) faces the highest rate of hypertension worldwide. Blood pressure (BP) control rests on the association of lifestyle modification and antihypertensive medicines. We aimed to systematically review antihypertensive strategies implemented in SSA to achieve BP control. A systematic search beginning in 2003 was performed in MEDLINE, COCHRANE and EMBASE. We included only original and observational studies in SSA countries. Thirty studies were included from 11 countries. No study was multinational. The number of patients varied from 111 to 897 (median: 294; IQR: 192-478). Overall, 21% of patients received monotherapy, 42.6% two-drug and 26.6% three-drug combinations. Out of all the strategies, renin-angiotensin system (RAS) blockers were mostly prescribed, followed by diuretics and calcium channel blockers. In monotherapy, RAS blockers were the first to be prescribed. Only 10 articles described antihypertensive strategies beyond triple combinations. BP control was highly variable (range: 16.4 to 61.2%). Multicentre studies performed in several SSA countries are needed to ensure international guidelines actually do improve outcomes in SSA.</p>","PeriodicalId":9434,"journal":{"name":"Cardiovascular Journal of Africa","volume":"34 ","pages":"307-317"},"PeriodicalIF":0.7000,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11040475/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Journal of Africa","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5830/CVJA-2022-065","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Sub-Saharan Africa (SSA) faces the highest rate of hypertension worldwide. Blood pressure (BP) control rests on the association of lifestyle modification and antihypertensive medicines. We aimed to systematically review antihypertensive strategies implemented in SSA to achieve BP control. A systematic search beginning in 2003 was performed in MEDLINE, COCHRANE and EMBASE. We included only original and observational studies in SSA countries. Thirty studies were included from 11 countries. No study was multinational. The number of patients varied from 111 to 897 (median: 294; IQR: 192-478). Overall, 21% of patients received monotherapy, 42.6% two-drug and 26.6% three-drug combinations. Out of all the strategies, renin-angiotensin system (RAS) blockers were mostly prescribed, followed by diuretics and calcium channel blockers. In monotherapy, RAS blockers were the first to be prescribed. Only 10 articles described antihypertensive strategies beyond triple combinations. BP control was highly variable (range: 16.4 to 61.2%). Multicentre studies performed in several SSA countries are needed to ensure international guidelines actually do improve outcomes in SSA.

撒哈拉以南非洲的高血压治疗:系统综述。
撒哈拉以南非洲(SSA)是全球高血压发病率最高的地区。血压控制主要依靠改变生活方式和降压药物。我们旨在系统回顾撒哈拉以南非洲地区为实现血压控制而实施的降压策略。从 2003 年开始,我们在 MEDLINE、COCHRANE 和 EMBASE 中进行了系统检索。我们仅纳入了 SSA 国家的原创性和观察性研究。共纳入 11 个国家的 30 项研究。没有一项研究是跨国的。患者人数从 111 到 897 不等(中位数:294;IQR:192-478)。总体而言,21%的患者接受了单一疗法,42.6%的患者接受了两药联合疗法,26.6%的患者接受了三药联合疗法。在所有治疗策略中,肾素-血管紧张素系统(RAS)阻滞剂占大多数,其次是利尿剂和钙通道阻滞剂。在单药治疗中,肾素血管紧张素系统(RAS)阻断剂是最先使用的药物。只有 10 篇文章介绍了三联疗法以外的降压策略。血压控制的差异很大(范围:16.4% 至 61.2%)。需要在几个撒哈拉以南非洲国家开展多中心研究,以确保国际指南确实能改善撒哈拉以南非洲国家的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiovascular Journal of Africa
Cardiovascular Journal of Africa CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.30
自引率
0.00%
发文量
0
审稿时长
4-8 weeks
期刊介绍: The Cardiovascular Journal of Africa (CVJA) is an international peer-reviewed journal that keeps cardiologists up to date with advances in the diagnosis and treatment of cardiovascular disease. Topics covered include coronary disease, electrophysiology, valve disease, imaging techniques, congenital heart disease (fetal, paediatric and adult), heart failure, surgery, and basic science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信